Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea announces partnership for antifungal isavuconazole in Japan with Asahi
Kasei Pharma
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Basilea grants Asahi Kasei Pharma exclusive license to develop and
commercialize isavuconazole in Japan
* Basilea eligible for upfront and milestone payments of up to CHF 67 million
and double-digit royalties
Basel, Switzerland, September 15, 2016 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced today that Basilea Pharmaceutica International Ltd. (Basilea) has
entered into a partnering agreement with Asahi Kasei Pharma Corporation (Asahi
Kasei Pharma) for Basilea's antifungal drug isavuconazole in Japan.
Under the terms of the agreement, Asahi Kasei Pharma is granted an exclusive
license to develop and commercialize isavuconazole in Japan. Basilea will
receive an upfront payment of CHF 7 million and will be eligible to receive up
to approximately CHF 60 million (at current exchange rate) of additional
payments upon achievement of regulatory and commercial milestones. Basilea will
also receive double-digit tiered royalties on product sales in Japan.
Asahi Kasei Pharma will be responsible for conducting clinical studies necessary
to apply for Japanese marketing authorization for isavuconazole for the
treatment of invasive aspergillosis and mucormycosis. It will purchase product
for commercialization of isavuconazole from Basilea.
Ronald Scott, Basilea's Chief Executive Officer, stated: "We are very pleased to
partner with Asahi Kasei Pharma, which has a proven track record in the
successful clinical development of innovative drugs and a strong commercial
presence in the hospital area, including intensive care units and hematology. We
look forward to making isavuconazole available to patients in this important
market. Isavuconazole may provide a new treatment option for patients in Japan
in this area of substantial unmet medical need."
About isavuconazole
Isavuconazole is an intravenous and oral azole antifungal and the active agent
of the prodrug isavuconazonium sulfate. Isavuconazole is approved in the United
States for patients 18 years of age and older in the treatment of invasive
aspergillosis and invasive mucormycosis.(1) In Europe, it received marketing
authorization for the treatment of adult patients with invasive aspergillosis
and for the treatment of adult patients with mucormycosis for whom amphotericin
B is inappropriate.(2) Basilea has licensed the US rights to Astellas Pharma
Inc. and the Japanese rights to Asahi Kasei Pharma Corporation. Basilea
commercializes isavuconazole as CRESEMBA(® )in Germany, Italy, the UK and
Austria and is seeking national pricing and reimbursement in additional EU
countries. The drug is commercialized in the US by Astellas Pharma US. Outside
the US and the EU, isavuconazole is currently an investigational product and not
approved for commercial use. The drug was co-developed by Basilea and Astellas.
About invasive aspergillosis and mucormycosis
Invasive aspergillosis and mucormycosis are life-threatening fungal infections
that predominantly affect immunocompromised patients, such as patients with
cancer. Invasive aspergillosis is known for high morbidity and mortality.
Mucormycosis (also known as zygomycosis) is a rapidly progressing and life-
threatening invasive fungal infection, known for high morbidity and mortality.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment options
in the therapeutic areas of bacterial infections, fungal infections and cancer.
The company uses the integrated research, development and commercial operations
of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop
and commercialize innovative pharmaceutical products to meet the medical needs
of patients with serious and potentially life-threatening conditions. Basilea
Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX
Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's
website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+-------------------------------------------------------+
| Peer Nils Schröder, PhD |
| Head of Corporate Communications & Investor Relations |
| +41 61 606 1102 |
| media_relations(at)basilea.com |
| investor_relations(at)basilea.com |
+-------------------------------------------------------+
This press release can be downloaded from www.basilea.com.
References
1. CRESEMBA(®) US prescribing information [Accessed: September 14, 2016]
2. European Public Assessment Report (EPAR) CRESEMBA(®):
http://www.ema.europa.eu [Accessed: September 14, 2016]
Press release (PDF):
http://hugin.info/134390/R/2042253/762235.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.09.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 494886
Anzahl Zeichen: 6782
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
